IL-6 has been shown to inhibit CCA proliferation through the JAK-STAT3 (Janus kinase-signal transducer and activator of transcription-3) pathway and reduce the activity of M2 TAMs [24], thereby enhancing antitumor effects. The gene discussed is STAT3; the disease is cholangiocarcinoma.